Cernilton treats benign prostatic hyperplasia (BPH) and chronic prostatitis.
South Korea based Dongkoo Bio & Pharma has signed a licensing-in deal with Swedish drugmaker AB Cernelle to sell Cernitol Novum, an over-the-counter (OTC) treatment for chronic prostatitis.
Under the agreement, the Korean drugmaker will exclusively supply and distribute Cernitol Novum not only in the local market but China, Taiwan, 10 ASEAN (Association of Southeast Asian Nations) countries, and six GCC (Gulf Cooperation Council) members such as Saudi Arabia and the United Arab Emirates.
Cernitol Novum is an OTC medication that doubled the efficacy of the active ingredient of Cernilton, which Dongkoo Bio & Pharma began importing in 1978 from AB Cernelle. Cernilton treats benign prostatic hyperplasia (BPH) and chronic prostatitis.
Dongkoo Bio & Pharma hopes that the latest OTC remedy will perform well in the domestic and overseas prostate treatment market.
Under the agreement, the Korean drugmaker will exclusively supply and distribute Cernitol Novum not only in the local market but China, Taiwan, 10 ASEAN (Association of Southeast Asian Nations) countries, and six GCC (Gulf Cooperation Council) members such as Saudi Arabia and the United Arab Emirates.
Cernitol Novum is an OTC medication that doubled the efficacy of the active ingredient of Cernilton, which Dongkoo Bio & Pharma began importing in 1978 from AB Cernelle. Cernilton treats benign prostatic hyperplasia (BPH) and chronic prostatitis.
Dongkoo Bio & Pharma hopes that the latest OTC remedy will perform well in the domestic and overseas prostate treatment market.
